{
  "id": 4782337,
  "title": "HLB's liver cancer therapy proves effective across all age groups in new study",
  "url": "https://urgent.news/2026/09/01/hlbs-liver-cancer-therapy-proves-effective-across-all-age-groups-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-01T04:27:02.000Z",
  "source": {
    "name": "The Korea Times",
    "slug": "the-korea-times-koreatimes",
    "url": "https://www.koreatimes.co.kr/business/companies/20260901/hlbs-liver-cancer-therapy-proves-effective-across-all-age-groups-in-new-study"
  },
  "original_language": "en",
  "account": "The HLB Group's liver cancer therapy, a combination of rivoceranib and camrelizumab, demonstrated consistent treatment benefits across all age groups in a new study. Presented at an upcoming international conference, the research from Elevar Therapeutics' U.S. subsidiary highlights the effectiveness of the drug combination in patients under 40. Median overall survival for younger patients reached 21.5 months, compared to 15.2 months for those on the standard treatment sorafenib. Progression-free survival, the time before the cancer worsens, was also significantly higher in the younger group at 5.5 months versus 2.7 months. Even for patients over 50, the therapy showed promising results with an overall survival rate of 23.9 months, compared to 1.",
  "summary": "HLB Group's liver cancer combination therapy showed consistent treatment benefits regardless of patient age, including in patients under 40, according to a new subgroup analysis to be presented this week at an international cancer conference. Elevar Therapeutics, HLB's U.S. subsidiary, will present an age-based post-hoc analysis of its global Phase 3 CARES-310 trial in a poster session at the…",
  "key_points": [
    "HLB Group's liver cancer therapy effective across all age groups",
    "Median overall survival 21.5 months for patients under 40",
    "Progression-free survival 5.5 months in younger patients"
  ],
  "editors_take": "The therapy's consistent effectiveness across all age groups suggests a potentially expanded treatment option for liver cancer patients, regardless of age, challenging traditional age-based therapy assessments.",
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "The Korea Times",
        "title": "HLB's liver cancer therapy proves effective across all age groups in new study",
        "url": "https://urgent.news/2026/09/01/hlbs-liver-cancer-therapy-proves-effective-across-all-age-groups-in-4787950",
        "published": "2026-09-01T05:07:03.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}